BioSpace News Archive

Cyteir Therapeutics, Inc. (“Cyteir” or the “Company”) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) today announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on Tuesday, August 1, 2023 after the financial markets close.

NLS Pharmaceutics Ltd. today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update.

Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for its fiscal 2023 year and (unaudited) fourth quarter ended March 31, 2023.

Chime Biologics announced that it has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.

Reneo Pharmaceuticals, Inc. today announced that the company’s management team will participate at the SVB Securities Therapeutics Forum.

As per 30 June 2023 , the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares.

Benzodiazepine use and discontinuation is associated with nervous system injury and negative life effects that continue after discontinuation, according to an article published 06/29/2023 in the open access journal PLOS ONE , noted the Alliance for Benzodiazepine Best Practices.

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call.